Fonadelpar - Senju Pharmaceutical

Drug Profile

Fonadelpar - Senju Pharmaceutical

Alternative Names: SJP 0035

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senju Pharmaceutical
  • Class Acetic acids; Benzoxazoles; Eye disorder therapies; Thiazoles
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Corneal disorders

Most Recent Events

  • 03 May 2017 Senju Pharmaceutical completes a phase IIa trial for Corneal disorders in USA (Ophthalmic) (NCT02929823)
  • 23 Mar 2017 Fonadelpar is still in phase II trials for Corneal disorders in USA (Ophthalmic)
  • 01 Sep 2016 Senju Pharmaceutical initiates a phase IIa trial for Corneal disorders in USA (Ophthalmic) (NCT02929823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top